T1	Participants 76 112	patients with chronic kidney disease
T2	Participants 194 229	patients with mild renal impairment
T3	Participants 386 450	patients who underwent percutaneous coronary intervention (PCI).
T4	Participants 494 612	patients enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial
